Defitelio (Defibrotide): Uses, Dosage & Side Effects
A vascular-protective antithrombotic agent for the treatment of hepatic veno-occlusive disease following stem cell transplantation
Defitelio (defibrotide) is a hospital-only prescription medication used to treat severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS). This serious condition occurs when blood vessels in the liver become damaged and blocked by blood clots, typically as a complication of the conditioning regimen given before hematopoietic stem cell transplantation (HSCT). Defibrotide works by protecting the vascular endothelium, promoting fibrinolysis (breakdown of blood clots), and restoring normal blood flow in the liver. It is administered as an intravenous infusion four times daily for at least 21 days under specialist supervision. Defitelio received conditional marketing authorization from the EMA in 2013 and FDA approval in 2016, based on its demonstrated ability to improve survival in patients with severe VOD.
Quick Facts: Defitelio
Key Takeaways
- Defitelio is the only approved treatment for severe hepatic VOD/SOS: It is specifically indicated for treating veno-occlusive disease with multi-organ dysfunction following hematopoietic stem cell transplantation in adults and children from 1 month of age.
- Hospital-only medication administered under specialist supervision: Defitelio is given as an intravenous infusion over 2 hours, four times daily, and must be initiated and monitored by experienced physicians at a transplant center.
- Bleeding is the primary safety concern: Due to its antithrombotic and profibrinolytic properties, Defitelio carries a significant risk of hemorrhage. Patients must be monitored closely for signs of bleeding throughout treatment.
- Must not be combined with thrombolytic agents: Concurrent use with tissue plasminogen activator (tPA) or other systemic thrombolytics is contraindicated due to unacceptable bleeding risk.
- Treatment continues for at least 21 days: Therapy should be maintained until symptoms of VOD have resolved completely. Early discontinuation may lead to disease relapse.
What Is Defitelio and What Is It Used For?
Defitelio (defibrotide) is a medication that protects blood vessel walls and prevents blood clots from forming in the liver. It is the only approved treatment for severe hepatic veno-occlusive disease (VOD), a potentially life-threatening complication that can occur after hematopoietic stem cell transplantation (HSCT).
Defibrotide is a complex mixture of single-stranded and double-stranded polydeoxyribonucleotides (fragments of DNA) derived from porcine intestinal mucosa. Although its precise mechanism of action is not fully elucidated, extensive research has demonstrated that defibrotide exerts multiple complementary effects on the vascular endothelium – the thin layer of cells lining blood vessels. These effects include protecting endothelial cells from damage, promoting the natural dissolution of blood clots (fibrinolysis), reducing inflammation, and restoring the delicate balance between clot formation and clot breakdown in injured blood vessels.
Hepatic veno-occlusive disease (VOD), also referred to as sinusoidal obstruction syndrome (SOS), is a serious condition in which the small blood vessels (hepatic sinusoids and venules) in the liver become damaged, inflamed, and blocked by blood clots. The resulting obstruction impedes blood flow through the liver, leading to liver enlargement, fluid accumulation in the abdomen (ascites), weight gain from fluid retention, jaundice (yellowing of the skin and eyes), and in severe cases, multi-organ failure. VOD most commonly occurs as a toxic complication of the high-dose chemotherapy and/or total body irradiation (the “conditioning regimen”) administered before hematopoietic stem cell transplantation.
The incidence of VOD following stem cell transplantation varies widely depending on the conditioning regimen, patient age, pre-existing liver disease, and the type of transplant, ranging from approximately 5% to 60% in different studies. Severe VOD with multi-organ dysfunction carries a mortality rate exceeding 80% without effective treatment, underscoring the critical need for Defitelio in transplant medicine. The drug was approved by the European Medicines Agency (EMA) under exceptional circumstances in 2013 and by the United States Food and Drug Administration (FDA) in 2016, making it the first and currently only medication specifically approved for this indication.
How Defibrotide Works
Defibrotide acts on the vascular endothelium through several interconnected mechanisms that together help restore normal blood flow in the damaged liver:
- Endothelial protection: Defibrotide stabilizes and protects endothelial cells from further damage caused by the conditioning regimen, reducing the release of pro-thrombotic and pro-inflammatory mediators
- Profibrinolytic activity: It increases the expression and activity of tissue plasminogen activator (tPA) and thrombomodulin on endothelial cells, promoting the enzymatic breakdown of existing blood clots within the hepatic vasculature
- Antithrombotic effects: Defibrotide reduces levels of plasminogen activator inhibitor-1 (PAI-1) and von Willebrand factor, both of which are elevated in VOD and promote clot formation. It also decreases thrombin generation and platelet activation
- Anti-inflammatory properties: The drug modulates endothelial cell activation and reduces the expression of adhesion molecules (P-selectin, E-selectin), thereby decreasing leukocyte recruitment and inflammatory injury to the liver
Defitelio was approved under “exceptional circumstances” by the EMA. This designation is used when a complete data package cannot be obtained because the disease is very rare and it would be unethical to conduct placebo-controlled clinical trials. The EMA reviews all new available data annually. Despite these limitations, clinical studies have demonstrated that defibrotide significantly improves survival in patients with severe VOD compared to historical controls.
What Should You Know Before Receiving Defitelio?
Before receiving Defitelio, your medical team must assess several important factors. Do not receive this medication if you are allergic to defibrotide or if you are currently being treated with thrombolytic agents (clot-dissolving drugs). Caution is required if you are taking anticoagulants or have active bleeding or hemodynamic instability.
Contraindications – Do Not Use Defitelio If You:
- Are allergic to defibrotide or any of the other ingredients in this medicine (sodium citrate, hydrochloric acid, sodium hydroxide, water for injections)
- Are currently receiving thrombolytic medications that dissolve blood clots, such as tissue plasminogen activator (tPA, alteplase), as the combination creates an unacceptable risk of severe hemorrhage
Warnings and Precautions
Talk to your doctor before receiving Defitelio if any of the following apply to you. These conditions may require additional monitoring, dose adjustments, or temporary interruption of treatment:
- Concurrent anticoagulant or antiplatelet therapy: If you are taking medications that increase bleeding risk (heparin, warfarin, direct oral anticoagulants, aspirin, NSAIDs), your medical team must weigh the benefits against the increased hemorrhage risk and monitor you closely
- Active or recent significant bleeding: Defitelio should be used with extreme caution in patients with active hemorrhage. If major bleeding occurs during treatment, the infusion should be stopped and the clinical team should reassess the benefit-risk balance before potentially resuming therapy
- Hemodynamic instability: If you have circulatory problems due to your body’s inability to maintain stable blood pressure, additional monitoring is required as Defitelio can further lower blood pressure
- Planned invasive procedures: If surgery or invasive procedures are necessary during treatment, your medical team may need to temporarily discontinue Defitelio due to the increased bleeding risk. Treatment can typically be resumed once adequate hemostasis is achieved
- Need for blood transfusion: If you require blood product transfusions for significant bleeding, your medical team will assess whether Defitelio should be temporarily withheld
Children and Adolescents
Defitelio can be used in children and adolescents from 1 month of age. The same dose per kilogram of body weight is used as in adults. Defitelio is not recommended for use in neonates younger than 1 month of age due to insufficient safety and efficacy data in this age group. The side effects observed in pediatric patients are expected to be similar in type, severity, and frequency to those seen in adult patients.
Pregnancy and Breastfeeding
There are limited data on the use of Defitelio during pregnancy. Do not receive Defitelio if you are pregnant unless your medical team determines that the potential benefit to you outweighs the potential risk to the unborn baby, as VOD itself is life-threatening and requires urgent treatment.
If you are of childbearing potential or your partner could become pregnant, both partners should use effective contraception during treatment with Defitelio and for at least 1 week after the last dose. Discuss appropriate contraceptive methods with your healthcare team.
It is not known whether defibrotide or its metabolites pass into breast milk. A risk to breastfed infants cannot be excluded. The decision whether to breastfeed during Defitelio treatment should be made by your medical team, taking into account the benefit of breastfeeding for the child and the benefit of treatment for the mother.
Driving and Operating Machinery
Defitelio is not expected to affect your ability to drive or operate machinery. However, as it is a hospital-only medication administered to acutely ill patients, this consideration is generally not relevant during the treatment period.
Each 2.5 ml vial of Defitelio contains 20.4 mg of sodium (a component of table salt). This corresponds to approximately 1.02% of the recommended maximum daily intake of sodium for adults. Your medical team will take this into account, particularly if you are on a sodium-restricted diet or receiving multiple vials per day.
How Does Defitelio Interact with Other Drugs?
Defitelio must not be used together with thrombolytic agents (e.g., tPA). It should be used with caution alongside anticoagulants (heparin, warfarin, DOACs), antiplatelet agents (aspirin, clopidogrel), and NSAIDs, as these combinations significantly increase the risk of bleeding.
Defibrotide has inherent antithrombotic and profibrinolytic properties. When combined with other medications that affect blood clotting or increase bleeding risk, the hemorrhagic potential is amplified. Your medical team will carefully evaluate all concurrent medications and adjust them as necessary during Defitelio treatment. The following table summarizes the most important drug interactions:
Contraindicated Combinations
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Tissue plasminogen activator (tPA, alteplase) | Combined thrombolytic and profibrinolytic activity creates extreme hemorrhage risk | Absolutely contraindicated; must not be co-administered under any circumstances |
| Other systemic thrombolytics (streptokinase, urokinase) | Synergistic clot-dissolving effects lead to uncontrolled bleeding | Contraindicated; do not use concurrently with Defitelio |
Caution Required – Increased Bleeding Risk
| Drug / Class | Interaction | Clinical Significance |
|---|---|---|
| Heparin (unfractionated and LMWH) | Combined anticoagulant and antithrombotic effects increase bleeding risk | Close monitoring for hemorrhage; dose adjustment or withholding may be needed |
| Warfarin | Additive effect on coagulation increases hemorrhage risk | Monitor INR closely; consider temporarily withholding warfarin |
| Direct oral anticoagulants (rivaroxaban, apixaban, dabigatran) | Combined anticoagulant effects increase bleeding risk | Carefully assess benefit-risk; monitor for signs of bleeding |
| Acetylsalicylic acid (aspirin) | Antiplatelet effects combined with Defitelio’s antithrombotic action increase hemorrhage risk | Use with caution; monitor for bleeding complications |
| NSAIDs (ibuprofen, naproxen, diclofenac) | Anti-inflammatory NSAIDs impair platelet function and can increase bleeding when combined with Defitelio | Avoid if possible; monitor closely if combination is necessary |
What Is the Correct Dosage of Defitelio?
Defitelio is administered as an intravenous infusion of 6.25 mg/kg body weight over 2 hours, four times daily (every 6 hours), giving a total daily dose of 25 mg/kg. Treatment continues for a minimum of 21 days and until VOD symptoms have fully resolved.
Defitelio must only be initiated and continuously supervised by an experienced physician at a hospital or specialist center for hematopoietic stem cell transplantation. The dosage is calculated based on the patient’s body weight and is the same for adults and children from 1 month of age. The medication is diluted in a compatible intravenous solution and administered as a slow intravenous infusion (drip) over exactly 2 hours.
Adults
Standard Dosing Regimen
The recommended dose is 6.25 mg/kg body weight per infusion, administered as an intravenous infusion over 2 hours. This dose is given four times daily (approximately every 6 hours), resulting in a total daily dose of 25 mg/kg. Treatment should continue for a minimum of 21 days. After 21 days, treatment should be continued until symptoms and signs of VOD have resolved completely. Your medical team will assess your clinical response regularly to determine when treatment can be safely discontinued.
Duration of Treatment
The minimum treatment duration is 21 days. In clinical studies, the median duration of treatment was approximately 21–23 days, though some patients required longer courses depending on the severity of their disease and clinical response. Treatment should not be discontinued prematurely, as this may lead to recurrence of VOD symptoms. Your medical team will decide when it is safe to stop treatment based on clinical assessment, laboratory parameters, and imaging findings.
Children and Adolescents (1 month to 18 years)
Pediatric Dosing
The recommended dose for children and adolescents aged 1 month to 18 years is the same as for adults: 6.25 mg/kg body weight per infusion, administered intravenously over 2 hours, four times daily. The total daily dose is 25 mg/kg. VOD can occur in pediatric transplant recipients, and the clinical presentation and treatment approach are similar to those in adults. Your child’s medical team will calculate the exact dose based on their current body weight.
Neonates
Defitelio is not recommended for use in neonates younger than 1 month of age. There is insufficient clinical evidence regarding the safety and efficacy of defibrotide in this age group.
Elderly Patients
No specific dose adjustment is required for elderly patients. However, elderly patients may be at increased risk for bleeding complications and may have reduced hepatic and renal function, necessitating closer monitoring during treatment. The same weight-based dosing regimen (6.25 mg/kg four times daily) applies regardless of age.
Preparation and Administration
Defitelio concentrate must be diluted before use. The required volume of concentrate is withdrawn from the vial(s) and added to a compatible intravenous solution (0.9% sodium chloride or 5% glucose solution) to achieve a final concentration suitable for infusion. The diluted solution should be administered within 24 hours if stored at 2–8°C, unless prepared under controlled aseptic conditions. Each infusion must be delivered over exactly 2 hours using an infusion pump or gravity drip, and the infusion line should be flushed with 0.9% sodium chloride or 5% glucose before and after the Defitelio infusion.
Missed Dose
Since Defitelio is administered by healthcare professionals in a hospital setting, it is unlikely that a dose will be missed. However, if a dose is inadvertently omitted, the next scheduled dose should be given at the usual time. A double dose must not be given to compensate for a missed dose. If you believe a dose has been missed, inform your doctor or nurse promptly.
No dose adjustments are recommended based on age, gender, renal impairment, or hepatic impairment. However, if clinically significant bleeding occurs, your medical team may temporarily interrupt the infusion. Treatment can typically be resumed once bleeding has stopped and the patient has been stabilized. The decision to restart is made on a case-by-case basis by the treating physician.
What Are the Side Effects of Defitelio?
Like all medicines, Defitelio can cause side effects, although not everybody gets them. The most common side effect is low blood pressure (hypotension). Bleeding events are the most clinically significant adverse effects, including nosebleeds, gastrointestinal bleeding, and bleeding from catheter sites. Contact your medical team immediately if you experience any unusual bleeding.
The side effects of Defitelio are primarily related to its antithrombotic and profibrinolytic mechanism of action. Bleeding events are the most important safety concern and can range from minor (e.g., nosebleeds, gum bleeding) to severe and life-threatening (e.g., intracranial hemorrhage, pulmonary hemorrhage). It is important to note that patients receiving Defitelio are typically critically ill following stem cell transplantation, and distinguishing drug-related adverse effects from the underlying disease and its complications can be challenging.
If you experience any of the following side effects, inform your medical team immediately. They will assess whether the benefit of continued treatment outweighs the risks and may temporarily interrupt or permanently discontinue the infusion if necessary.
Very Common Side Effects
May affect more than 1 in 10 people
- Low blood pressure (hypotension)
Common Side Effects
May affect up to 1 in 10 people
- Hemorrhage (bleeding) – general
- Nosebleeds (epistaxis)
- Cerebral hemorrhage (bleeding in the brain)
- Gastrointestinal hemorrhage (bleeding in the stomach or intestines)
- Hematemesis (vomiting blood)
- Pulmonary hemorrhage (bleeding in the lungs)
- Catheter-site bleeding (bleeding from infusion lines)
- Hematuria (blood in the urine)
- Oral hemorrhage (bleeding from the mouth)
- Cutaneous hemorrhage (bleeding in the skin)
- Coagulopathy (impaired blood clotting)
- Nausea
- Vomiting
- Diarrhea
- Skin rash
- Pruritus (itching)
- Pyrexia (fever)
Uncommon Side Effects
May affect up to 1 in 100 people
- Eye hemorrhage (bleeding from the eyes)
- Melena (blood in stools, appearing as dark tarry stools)
- Injection site hemorrhage
- Cerebral hematoma (localized collection of blood in the brain)
- Hemothorax (accumulation of blood between the heart and lungs)
- Ecchymosis (bruising)
- Allergic reactions (may present as skin rash, hives, or itching)
- Anaphylactic reaction (severe allergic reaction with swelling of hands, face, lips, tongue, or throat, difficulty breathing)
- Unusual or unexplained bleeding or bruising
- Black tarry stools or blood in vomit
- Coughing up blood
- Severe headache, confusion, or visual disturbances (possible signs of cerebral hemorrhage)
- Swelling of the face, lips, tongue, or throat with difficulty breathing (anaphylaxis)
- Severe skin rash or hives with breathing difficulties
It is important to report suspected adverse reactions after the medicine has been authorized. Reporting helps the continuous monitoring of the benefit-risk balance. Healthcare professionals and patients can report suspected side effects to their national medicines regulatory authority (e.g., FDA MedWatch in the US, Yellow Card Scheme in the UK, or EMA EudraVigilance in the EU).
How Should You Store Defitelio?
Defitelio concentrate should be stored below 25°C (77°F) and must not be frozen. After dilution, the infusion solution may be stored for up to 24 hours at 2–8°C. Keep out of sight and reach of children.
As a hospital-only medication, Defitelio is stored, prepared, and administered by trained healthcare professionals. However, the following storage guidelines ensure the medication remains safe and effective:
- Unopened vials: Store at room temperature, not exceeding 25°C (77°F). Do not freeze. Keep the vials in the original carton to protect from light.
- After dilution: The diluted infusion solution should be used within 24 hours if stored at 2–8°C (36–46°F), unless preparation was carried out under controlled and validated aseptic conditions.
- Visual inspection: Do not use Defitelio if the solution appears cloudy, discolored, or contains visible particles. The concentrate should be a clear, light yellow to brown solution.
- Expiry date: Do not use after the expiry date (EXP) stated on the carton and vial label. The expiry date refers to the last day of the stated month.
- Children: Keep out of the sight and reach of children at all times.
- Disposal: Do not dispose of unused medication in household waste or sewage. Any unused product or waste material should be disposed of in accordance with local requirements for pharmaceutical waste.
What Does Defitelio Contain?
Each 2.5 ml vial of Defitelio contains 200 mg of defibrotide as the active substance (80 mg per ml). The solution also contains sodium citrate, hydrochloric acid, sodium hydroxide, and water for injections.
Active Ingredient
The active substance is defibrotide. Defibrotide is a complex mixture of single-stranded and double-stranded polydeoxyribonucleotides (oligonucleotide fragments) obtained from porcine intestinal mucosa through a controlled depolymerization process. Each glass vial contains 2.5 ml of concentrate, providing 200 mg of defibrotide. The concentration is 80 mg/ml.
Inactive Ingredients (Excipients)
The other ingredients in Defitelio are:
- Sodium citrate (dihydrate) – a buffering agent that maintains the pH of the solution
- Hydrochloric acid – used for pH adjustment
- Sodium hydroxide – used for pH adjustment
- Water for injections – the solvent
Appearance and Packaging
Defitelio is a clear, light yellow to brown concentrate for solution for infusion (sterile concentrate), free from visible particles or cloudiness. Each carton contains 10 glass vials, each containing 2.5 ml of concentrate. The vials are single-use only; any unused solution should be discarded.
This medicine contains 20.4 mg sodium per vial, equivalent to approximately 1.02% of the WHO recommended maximum daily intake of 2 g sodium for adults. When multiple vials are administered daily (as is typical with weight-based dosing), the total sodium intake from Defitelio should be considered, particularly in patients on sodium-restricted diets.
Frequently Asked Questions About Defitelio
Defitelio (defibrotide) is used to treat severe hepatic veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS). This is a serious, potentially life-threatening condition in which the blood vessels in the liver become damaged and blocked by blood clots. VOD most commonly occurs as a complication of the conditioning regimen (high-dose chemotherapy and/or radiation) given before hematopoietic stem cell transplantation (bone marrow transplant). Defibrotide works by protecting the blood vessel lining, promoting the breakdown of existing clots, and restoring blood flow in the liver. It is the only specifically approved treatment for this condition.
Defitelio is given as a slow intravenous infusion (drip) over 2 hours. The dose is 6.25 mg/kg body weight per infusion, administered four times daily (approximately every 6 hours), giving a total daily dose of 25 mg/kg. Treatment is initiated and supervised by a specialist physician at a hospital or transplant center. The minimum treatment duration is 21 days, and treatment continues until the symptoms and signs of veno-occlusive disease have completely resolved. In clinical studies, the average treatment duration was approximately 21–23 days.
Yes, Defitelio can be used in children and adolescents aged 1 month to 18 years. The dose per kilogram of body weight is the same as for adults (6.25 mg/kg per infusion, four times daily). VOD is a recognized complication of stem cell transplantation in pediatric patients, and defibrotide is an important treatment option for this population. Defitelio is not recommended for neonates younger than 1 month due to insufficient safety and efficacy data.
The primary risk of Defitelio treatment is bleeding (hemorrhage). Because defibrotide has antithrombotic and clot-dissolving properties, it can increase the risk of various types of bleeding, including nosebleeds, gastrointestinal bleeding, bleeding in the brain, pulmonary hemorrhage, and bleeding from catheter insertion sites. Other common side effects include low blood pressure, nausea, vomiting, diarrhea, skin rash, and fever. Rare but serious allergic reactions, including anaphylaxis, have also been reported. Your medical team will monitor you closely throughout treatment for any signs of bleeding or other adverse effects.
Hepatic veno-occlusive disease (VOD), now more commonly called sinusoidal obstruction syndrome (SOS), is a serious condition affecting the liver. It occurs when the small blood vessels inside the liver (sinusoids and hepatic venules) become damaged, inflamed, and blocked by blood clots and cellular debris. This blocks normal blood flow through the liver, causing it to enlarge painfully. Symptoms include rapid weight gain from fluid retention, abdominal swelling (ascites), and jaundice (yellowing of the skin and eyes). In severe cases, it can lead to multi-organ failure, which is fatal in over 80% of cases without treatment. VOD is most commonly caused by the high-dose chemotherapy and/or radiation used as conditioning before stem cell transplantation.
Using blood thinners (anticoagulants) alongside Defitelio increases the risk of bleeding and requires careful medical supervision. Thrombolytic agents such as tissue plasminogen activator (tPA) are absolutely contraindicated and must never be used together with Defitelio. Other anticoagulants (heparin, warfarin, rivaroxaban, apixaban, dabigatran) and antiplatelet medications (aspirin, NSAIDs) can be used concurrently only if the medical team determines that the benefit outweighs the risk, and with close monitoring for hemorrhagic complications. Your healthcare team will continuously assess your bleeding risk during treatment.
References
- 1 European Medicines Agency (EMA). “Defitelio (defibrotide) – Summary of Product Characteristics.” European Medicines Agency, 2024. Available at: ema.europa.eu/en/medicines/human/EPAR/defitelio
- 2 U.S. Food and Drug Administration (FDA). “Defitelio (defibrotide sodium) – Prescribing Information.” FDA, 2016. Available at: accessdata.fda.gov
- 3 Richardson PG, Riches ML, Kernan NA, et al. “Phase 3 trial of defibrotide for the treatment of severe veno-occlusive disease and multi-organ failure.” Blood. 2016;127(13):1656–1665. doi:10.1182/blood-2015-10-676924
- 4 Mohty M, Malard F, Abecasis M, et al. “Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation.” Bone Marrow Transplant. 2016;51(7):906–912. doi:10.1038/bmt.2016.130
- 5 Corbacioglu S, Cesaro S, Faraci M, et al. “Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial.” Lancet. 2012;379(9823):1301–1309. doi:10.1016/S0140-6736(11)61938-7
- 6 Carreras E, Diaz-Beya M, Rosinol L, et al. “The incidence of veno-occlusive disease following allogeneic hematopoietic stem cell transplantation has diminished and the outcome improved over the last decade.” Biol Blood Marrow Transplant. 2011;17(11):1713–1720. doi:10.1016/j.bbmt.2011.06.006
- 7 European Society for Blood and Marrow Transplantation (EBMT). “EBMT Handbook: Sinusoidal Obstruction Syndrome/Hepatic Veno-Occlusive Disease.” EBMT, 2024.
- 8 World Health Organization (WHO). “WHO Model List of Essential Medicines – 23rd List.” WHO, 2023.
Editorial Team
This article has been developed by the iMedic Medical Editorial Team, comprising licensed physicians, pharmacists, and medical writers with expertise in hematology, transplant medicine, and clinical pharmacology. All content is based on peer-reviewed research, international guidelines (EMA, FDA, EBMT), and established medical evidence.
All drug information undergoes a rigorous multi-step review process: initial drafting by medical writers, clinical accuracy review by specialist physicians, pharmacological verification, and final editorial approval. Content is updated whenever new evidence or regulatory changes become available.
iMedic receives no funding from pharmaceutical companies. Our editorial team has no financial relationships with the manufacturers of Defitelio or any competing products. All content decisions are made solely based on medical evidence and patient benefit.